Anil Balani, MD
Gastroenterology · Pennington, NJNPI 1972779098
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $116,602 of the $126,342 with a category attached, or 92.3%. AbbVie accounts for 71.8% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $35,492, more than ten times the $2,840 reported in 2019. Among gastroenterology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $789.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$91K
- Johnson & Johnson$29K
- Pfizer$7K
- Takeda Pharmaceuticals U.S.A., Inc.$57
- Daiichi Sankyo Inc.$35
- Bristol Myers Squibb$25
- plus $103 from 6 others
Across 9 payments — averaging $1839.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$15K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
What the payments were for
- Speaking & faculty fees$116,60292%
- Travel & lodging$5,0144%
- Food & beverage$4,7264%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 105 | $90,722 |
| Johnson & Johnson | 40 | $28,798 |
| Pfizer | 2 | $6,600 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Bristol Myers Squibb | 2 | $25 |
| Lilly USA, LLC | 1 | $21 |
| Sanofi | 1 | $19 |
| Ambu Inc. | 1 | $17 |
| Organon | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,342 in reported general payments places this provider in the 95th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 74 | $1,837,239 |
| Skyrizi On-BodyRisankizumab-Rzaa | 13 | $272,154 |
| Humira(Cf) PenAdalimumab | 13 | $209,506 |
| Entyvio PenVedolizumab | 11 | $69,022 |
| Mesalamine | 42 | $34,079 |
| LinzessLinaclotide | 11 | $10,390 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 44 | $7,562 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 74 | $4,440 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 13 | $1,349 |
| Sulfasalazine | 11 | $997 |
| Pantoprazole Sodium | 62 | $783 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 24 | $674 |
| Omeprazole | 54 | $442 |
| Esomeprazole Magnesium | 26 | $433 |
| Dicyclomine Hcl | 21 | $338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $28,798 | $1,837,23974 claims |
| AbbVieLinzess | $90,722 | $10,39011 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $16 | $7,56244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Pennington
- Jason RogartPennington$22K
- Vinod RustgiNew Brunswick$431K
- Zamir BrelviNewark$391K
- Adam ElfantMount Laurel$385K
- Devjit NayarHoboken$258K
- Lea ChenNew Brunswick$185K
- Alexander PerelmanWest Orange$160K
- Barry KaufmanEgg Harbor Township$157K
- Anish ShethPrinceton$151K
- Ramesh GuptaFair Lawn$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.